Skip to main content

Table 2 Standardized effect sizes by individual SIB domains for the overall study population and patient subgroups (intent-to-treat population, last observation carried forward)

From: Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity

Severe Impairment Battery (SIB) domain

 

Mini-Mental State Examination score

  

0 to 20

0 to 16

0 to 5

6 to 10

11 to 15

16 to 20

Language

LS mean treatment difference

0.903

1.310 (0.63 to

2.602

1.686

0.691

0.141

 

(95% CI)*

(0.38 to 1.43)

1.99)

(0.17 to 5.04)

(0.25 to 3.12)

(-0.19 to 1.57)

(-0.40 to 0.68)

 

Standardized effect size†

 

0.253 (5.171)

  

0.152

0.045

 

(pooled SD)

0.191

 

0.396

0.289

(4.558)

(3.150)

  

(4.736)

 

(6.571)

(5.828)

  

Memory

LS mean treatment difference

0.269

0.421

0.871 (-0.19

0.249 (-0.44

0.237 (-0.22 to

0.087 (-0.32 to

 

(95% CI)*

(-0.02 to 0.56)

(0.07 to 0.77)

to 1.93)

to 0.94)

0.69)

0.50)

 

Standardized effect size†

 

0.155 (2.711)

0.304 (2.863)

0.086 (2.893)

0.093 (2.534)

0.035 (2.469)

 

(pooled SD)

0.101

     
  

(2.675)

     

Praxis

LS mean treatment difference

0.216

0.252 (-0.02 to

0.854 (0.10 to

0.238 (-0.34

0.099 (-0.27 to

0.108 (-0.16 to

 

(95% CI)*

(-0.00 to 0.43)

0.52)0.115

1.61)0.415

to 0.81)0.099

0.47)0.046

0.37)0.061

 

Standardized effect size†

 

(2.192)

(2.060)

(2.417)

(2.148)

(1.753)

 

(pooled SD)

0.104

     
  

(2.077)

     

Visuospatial ability

LS mean treatment difference

0.195

0.311

0.576 (-0.36

0.506 (-0.04

-0.004 (-0.30

0.049 (-0.16 to

 

(95% CI)*

(0.00 to 0.39)

(0.06 to 0.56)

to 1.51)0.221

to 1.05)0.230

to 0.29)-0.002

0.26)

 

Standardized effect size†

 

0.161 (1.934)

(2.603)

(2.198)

(1.634)

0.039 (1.284)

 

(pooled SD)

0.110

     
  

(1.772)

     

Attention

LS mean treatment difference

0.123

0.179

0.211 (-0.33

0.098 (-0.26

0.240 (0.02 to

0.032 (-0.17 to

 

(95% CI)*

(-0.02 to

(0.01 to 0.35)

to 0.76)0.141

to 0.46)0.064

0.46)0.195

0.23)0.026

 

Standardized effect size

0.26)0.093

0.132

(1.500)

(1.516)

(1.233)

(1.231)

 

(pooled SD)

(1.326)

(1.357)

    

Orientation

LS mean treatment difference

0.038 (-0.10

0.056 (-0.11 to

-0.028 (-0.45

-0.003 (-0.31

0.152 (-0.08 to

-0.033 (-0.24

 

(95% CI)*

to 0.18)0.028

0.22)0.041

to 0.40)-0.024

to 0.30)-0.002

0.38)0.105

to 0.18)-0.025

 

Standardized effect size†

(1.354)

(1.367)

(1.160)

(1.352)

(1.445)

(1.290)

 

(pooled SD)

      

Social interaction

LS mean treatment difference

-0.003 (-0.10

0.028

0.423 (-0.16

-0.077 (-0.35

-0.071 (-0.22

-0.064 (-0.18

 

(95% CI)*

to 0.10)-0.003

(-0.10 to

to 1.00)0.273

to 0.20)-0.065

to 0.08)-0.075

to 0.05)-0.084

 

Standardized effect size†

(1.012)

0.16)0.026

(1.547)

(1.189)

(0.956)

(0.762)

 

(pooled SD)

 

(1.086)

    

Construction

LS mean treatment difference

0.139 (0.04 to

0.176 (0.04 to

0.505 (0.04 to

0.220 (-0.10

0.053 (-0.10 to

0.062 (-0.04 to

 

(95% CI)*

0.24)0.146

0.31)0.168

0.97)0.395

to 0.54)0.166

0.21)0.061

0.16)0.097

 

Standardized effect size†

(0.951)

(1.045)

(1.280)

(1.324)

(0.863)

(0.642)

 

(pooled SD

      

Orienting to name

LS mean treatment difference

-0.026 (-0.08

-0.024 (-0.10 to

0.050 (-0.22

-0.043 (-0.18

-0.046 (-0.14

-0.023 (-0.10

 

(95% CI)*

to 0.03)-0.042

0.05)-0.037

to 0.32)0.065

to 0.10)-0.063

to 0.05)-0.080

to 0.05)-0.038

 

Standardized effect size†

(0.635)

(0.642)

(0.771)

(0.690)

(0.579)

(0.601)

 

(pooled SD)

      

Total SIB

LS mean treatment difference

2.152 (1.06 to

3.141 (1.74 to

6.048 (1.04

3.258 (0.30 to

1.697 (-0.11 to

0.504 (-0.67 to

 

(95% CI)

3.24)0.218

4.54)0.296

to11.05)0.460

6.21)0.273

3.51)0.181

1.68)0.076

 

Standardized effect size†

(9.864)

(10.619)

(13.150)

(11.941)

(9.376)

(6.657)

 

(pooled SD)

      
  1. *Difference between donepezil 23 mg/day and 10 mg/day treatment groups for the score change from baseline to week 24; †positive standardized effect sizes represent superiority of donepezil 23 mg/day dose over 10 mg/day dose. LS, least squares.